LRRK2 kinase inhibitor treatment ameliorated the phenotype in transgenic and control mice (Takagawa et al., 2018), pointing to a role for the LRRK2 kinase activity in IBD pathogenesis. This evidence concerns the gene LRRK2 and inflammatory bowel disease.